Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Change in Accured Expenses (2017 - 2025)

Historic Change in Accured Expenses for AC Immune (ACIU) over the last 9 years, with Q3 2025 value amounting to $645038.4.

  • AC Immune's Change in Accured Expenses fell 4439.22% to $645038.4 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year decrease of 6452.21%. This contributed to the annual value of $5.7 million for FY2021, which is 80689.8% up from last year.
  • As of Q3 2025, AC Immune's Change in Accured Expenses stood at $645038.4, which was down 4439.22% from $399811.7 recorded in Q2 2025.
  • In the past 5 years, AC Immune's Change in Accured Expenses ranged from a high of $3.3 million in Q4 2021 and a low of -$5.6 million during Q1 2022
  • Over the past 5 years, AC Immune's median Change in Accured Expenses value was $480514.6 (recorded in 2022), while the average stood at $209092.4.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first soared by 422227.19% in 2021, then tumbled by 374687.11% in 2025.
  • Over the past 5 years, AC Immune's Change in Accured Expenses (Quarter) stood at $3.3 million in 2021, then tumbled by 83.23% to $561217.5 in 2022, then rose by 7.93% to $605701.6 in 2023, then surged by 91.51% to $1.2 million in 2024, then tumbled by 44.39% to $645038.4 in 2025.
  • Its Change in Accured Expenses stands at $645038.4 for Q3 2025, versus $399811.7 for Q2 2025 and -$1.1 million for Q1 2025.